Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELYM NASDAQ:GELS NASDAQ:SCYX NASDAQ:SPRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELYMEliem Therapeutics$1.28+1.6%$1.25$2.35▼$11.55$38.08M-0.39486,688 shs158,764 shsGELSGelteq$1.91+0.5%$1.78$0.77▼$5.50$18.03MN/A1.48 million shs128,274 shsSCYXSCYNEXIS$0.68-3.7%$0.83$0.66▼$2.29$26.38M1.57161,852 shs196,501 shsSPROSpero Therapeutics$3.08+4.6%$1.94$0.51▼$3.20$171.92M1.331.21 million shs1.17 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELYMEliem Therapeutics0.00%+3.23%-7.91%+13.27%-81.12%GELSGelteq+13.77%+7.95%+12.43%+110.64%+189,999,900.00%SCYXSCYNEXIS+0.37%+1.34%-22.61%-17.51%-63.00%SPROSpero Therapeutics+1.38%+1.38%+17.60%+398.39%+131.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELYMEliem TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AGELSGelteqN/AN/AN/AN/AN/AN/AN/AN/ASCYXSCYNEXIS0.2692 of 5 stars0.03.00.00.00.00.80.6SPROSpero Therapeutics3.8818 of 5 stars3.35.00.04.70.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELYMEliem Therapeutics 0.00N/AN/AN/AGELSGelteq 0.00N/AN/AN/ASCYXSCYNEXIS 0.00N/AN/AN/ASPROSpero Therapeutics 2.50Moderate Buy$5.0062.60% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELYMEliem TherapeuticsN/AN/AN/AN/A$3.90 per shareN/AGELSGelteq$100K180.30N/AN/A$1.30 per share1.47SCYXSCYNEXIS$3.75M7.12N/AN/A$1.45 per share0.47SPROSpero Therapeutics$47.98M3.58N/AN/A$0.85 per share3.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELYMEliem Therapeutics-$35.12M-$0.53N/A∞N/AN/A-47.03%-45.97%N/AGELSGelteq-$2.33MN/A0.00∞N/AN/AN/AN/AN/ASCYXSCYNEXIS-$21.29M-$0.56N/A13.68N/A-1,030.04%-53.47%-32.86%8/6/2025 (Estimated)SPROSpero Therapeutics-$68.57M-$1.28N/AN/AN/A-156.48%-123.50%-58.96%8/4/2025 (Estimated)Latest GELS, ELYM, SCYX, and SPRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q2 2025SPROSpero Therapeutics-$0.35N/AN/AN/AN/AN/A5/15/2025Q1 2025SCYXSCYNEXIS-$0.23-$0.17+$0.06-$0.11$0.14 million$0.26 million5/13/2025Q1 2025SPROSpero Therapeutics-$0.55-$0.25+$0.30-$0.25$11.00 million$5.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELYMEliem TherapeuticsN/AN/AN/AN/AN/AGELSGelteqN/AN/AN/AN/AN/ASCYXSCYNEXISN/AN/AN/AN/AN/ASPROSpero TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELYMEliem TherapeuticsN/A60.4160.41GELSGelteqN/A0.79N/ASCYXSCYNEXISN/A5.835.83SPROSpero TherapeuticsN/A2.562.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELYMEliem Therapeutics69.76%GELSGelteqN/ASCYXSCYNEXIS54.37%SPROSpero Therapeutics25.60%Insider OwnershipCompanyInsider OwnershipELYMEliem Therapeutics4.70%GELSGelteqN/ASCYXSCYNEXIS4.86%SPROSpero Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELYMEliem Therapeutics929.75 million28.35 millionNot OptionableGELSGelteqN/A9.44 millionN/AN/ASCYXSCYNEXIS6039.02 million37.12 millionOptionableSPROSpero Therapeutics15055.91 million52.84 millionOptionableGELS, ELYM, SCYX, and SPRO HeadlinesRecent News About These CompaniesSpero Therapeutics (NASDAQ:SPRO) Stock Passes Above Fifty Day Moving Average - What's Next?July 1, 2025 | marketbeat.comWhile institutions own 20% of Spero Therapeutics, Inc. (NASDAQ:SPRO), retail investors are its largest shareholders with 54% ownershipJune 28, 2025 | finance.yahoo.comSpero Therapeutics, Inc. (SPRO) Cash Flow - Yahoo FinanceJune 26, 2025 | finance.yahoo.comSpero Therapeutics (NASDAQ:SPRO) Upgraded to "Hold" at Wall Street ZenJune 21, 2025 | marketbeat.comSpero Therapeutics (NASDAQ:SPRO) Shares Pass Above 200 Day Moving Average - What's Next?June 19, 2025 | marketbeat.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Short Interest Up 446.6% in MayJune 11, 2025 | marketbeat.comSpero Therapeutics -- Additional Upside Potential Following Positive Phase 3 ResultsJune 11, 2025 | seekingalpha.comWhy Spero Therapeutics, Inc. (SPRO) Surged Last WeekMay 31, 2025 | msn.comWhy Spero Therapeutics, Inc. (SPRO) Surged Last WeekMay 31, 2025 | insidermonkey.comGSK & Spero Therapeutics announce PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by IDMCMay 30, 2025 | pharmabiz.comPSpero Therapeutics rockets on positive Phase III study for tebipenem HBrMay 29, 2025 | thepharmaletter.comTSpero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 MilestoneMay 29, 2025 | msn.comSPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study GoalMay 29, 2025 | zacks.comGSK, Spero report Phase 3 win for UTI antibiotic; Spero's stock soarsMay 28, 2025 | endpts.comEGSK's $66M bet on Spero's rejected UTI antibiotic pays off with a phase 3 winMay 28, 2025 | fiercebiotech.comFSpero Therapeutics Shares Soar as Trial with GSK Ends Early on EfficacyMay 28, 2025 | marketwatch.comSpero Therapeutics Stock Skyrockets on Strong Phase 3 Trial ResultsMay 28, 2025 | msn.comSpero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring CommitteeMay 28, 2025 | globenewswire.comSpero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue EstimatesMay 13, 2025 | zacks.comSpero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business UpdateMay 13, 2025 | globenewswire.comSpero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025May 5, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGELS, ELYM, SCYX, and SPRO Company DescriptionsEliem Therapeutics NASDAQ:ELYM$1.28 +0.02 (+1.59%) As of 07/3/2025Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.Gelteq NASDAQ:GELS$1.91 +0.01 (+0.53%) As of 02:17 PM EasternGelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.SCYNEXIS NASDAQ:SCYX$0.68 -0.03 (-3.72%) As of 02:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.Spero Therapeutics NASDAQ:SPRO$3.08 +0.14 (+4.59%) As of 02:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound Rises as Short Sellers Exit and AI Demand Grows Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? Robinhood Stock Gets 5 Price Target Upgrades, Signaling Upside AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
